Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06116968 is registered in ClinicalTrials.gov with Corxel Pharmaceuticals as lead sponsor.

NCT NCT06116968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06116968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Lead sponsor
Corxel Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 14, 2023
Completion date
October 20, 2025
Enrollment
40 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive hypertrophic cardiomyopathy